AstraZeneca on Friday introduced FluMist Home, a direct-to-consumer service that ships its needle-free FluMist nasal spray vaccine to eligible recipients’ doors. The program makes the 22-year-old influenza vaccine available for self- or caregiver administration in 34 states—marking the first time most Americans can complete a flu vaccination entirely at home. Adults aged 18 to 49 may self-administer FluMist, while caregivers can deliver it to children as young as two. Orders are placed online, reviewed by a licensed health-care provider and dispatched in temperature-controlled packaging with instructions for storage and use. The U.S. Food and Drug Administration cleared FluMist for self-administration in September 2024 after usability studies showed all participants could deliver a full dose correctly. AstraZeneca hopes the at-home option will help lift flu-shot uptake, which hovers below 50 percent among adults, following a 2024-25 season that caused an estimated 610,000 hospitalisations and 27,000 deaths, according to preliminary Centers for Disease Control and Prevention data. FluMist is covered by most commercial insurance plans; consumers pay an $8.99 shipping fee, while uninsured customers can purchase the vaccine for roughly $70. The company aims to expand distribution beyond the initial 34 states as local pharmacy rules permit.